Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
Enrico Derenzini(University of Milan), Pier Luigi Zinzani(Istituto di Ematologia di Bologna)
Cited by 58
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
|Journal of Clinical Oncology|2012|261
Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas
|Journal of Clinical Oncology|2006|230